Recipharm invests in its pMDI valves production capacity
Recipharm, a leading contract development and manufacturing organisation (CDMO), has announced an investment into its King’s Lynn, UK facility, which specialises in inhalation and nasal device development and manufacturing, under the brand Bespak by Recipharm.
The investment will expand the company’s pressurised metered dose inhaler (pMDI) valves production capacity and is set to come on stream in late 2021, further reinforcing the facility’s already robust operations.
The investment follows the acquisition of Consort Medical earlier this year and the subsequent launch of Recipharm’s specialist medical device brand, Bespak by Recipharm.
Keyvan Djamarani, CEO of Bespak, said, “The demand for pMDI valves has increased significantly over the last years and we are committed to supporting this growth from our Kings Lynn operation. The investment is a great opportunity to translate our acquisition into new high-quality profitable business and accelerate growth within our Advance Delivery Systems segment”.
“The acquisition of Consort has also allowed Recipharm to build a truly integrated platform of inhalation services. This expansion will bolster our offering even further by ensuring we are able to fulfil the forecasted increase in demand for respiratory devices whilst enabling our development team to support customers in inhalation and nasal drug development. In parallel, we are offering support to customers in using new more environmentally friendly propellants in their pMDIs”, said Jean-François Hilaire, Executive Vice President, Strategy & Global Integration at Recipharm.
Bespak by Recipharm’s inhaler and nasal technologies expertise form part of Recipharm Inhalation Solutions™, an end-to-end solution spanning early phase development to commercial manufacture of both inhalation drug product and device.
Jean-Francois Hilaire, Executive Vice President, Strategy & Global Integration, email@example.com, +33 695 447 507
Keyvan Djamarani, CEO Bespak, firstname.lastname@example.org, +44 155 369 3421
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com